WBA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -0.67% compared to Walgreens Boots Alliance's net margin of 10.87%. Walgreens Boots Alliance's return on equity of -53.86% beat Biogen's return on equity of 10.33%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 10.15%. On the other hand Biogen has an analysts' consensus of $200.12 which suggests that it could grow by 51.57%. Given that Biogen has higher upside potential than Walgreens Boots Alliance, analysts believe Biogen is more attractive than Walgreens Boots Alliance.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 8.96%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $39.5B, which are larger than Biogen quarterly revenues of $2.5B. Walgreens Boots Alliance's net income of -$265M is lower than Biogen's net income of $266.7M. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Biogen's PE ratio is 11.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 1.99x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Chimerix has a net margin of -0.67% compared to Walgreens Boots Alliance's net margin of -40270.18%. Walgreens Boots Alliance's return on equity of -53.86% beat Chimerix's return on equity of -56.65%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 10.15%. On the other hand Chimerix has an analysts' consensus of $8.54 which suggests that it could grow by 0.47%. Given that Walgreens Boots Alliance has higher upside potential than Chimerix, analysts believe Walgreens Boots Alliance is more attractive than Chimerix.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison Chimerix has a beta of -0.176, suggesting its less volatile than the S&P 500 by 117.551%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 8.96%. Chimerix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Chimerix pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $39.5B, which are larger than Chimerix quarterly revenues of $57K. Walgreens Boots Alliance's net income of -$265M is lower than Chimerix's net income of -$23M. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Chimerix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus -- for Chimerix. Usually stocks with elevated PS ratios are considered overvalued.

CVS Health has a net margin of -0.67% compared to Walgreens Boots Alliance's net margin of 1.68%. Walgreens Boots Alliance's return on equity of -53.86% beat CVS Health's return on equity of 6.12%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 10.15%. On the other hand CVS Health has an analysts' consensus of $72.26 which suggests that it could grow by 6.29%. Given that Walgreens Boots Alliance has higher upside potential than CVS Health, analysts believe Walgreens Boots Alliance is more attractive than CVS Health.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison CVS Health has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.622%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 8.96%. CVS Health offers a yield of 3.91% to investors and pays a quarterly dividend of $0.67 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. CVS Health pays out 73.1% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Walgreens Boots Alliance quarterly revenues are $39.5B, which are smaller than CVS Health quarterly revenues of $97.7B. Walgreens Boots Alliance's net income of -$265M is lower than CVS Health's net income of $1.6B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while CVS Health's PE ratio is 18.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 0.23x for CVS Health. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -0.67% compared to Walgreens Boots Alliance's net margin of -117.16%. Walgreens Boots Alliance's return on equity of -53.86% beat Moderna's return on equity of -29.09%.

Walgreens Boots Alliance has a consensus price target of $12.29, signalling upside risk potential of 10.15%. On the other hand Moderna has an analysts' consensus of $53.44 which suggests that it could grow by 96.76%. Given that Moderna has higher upside potential than Walgreens Boots Alliance, analysts believe Moderna is more attractive than Walgreens Boots Alliance.

Walgreens Boots Alliance has a beta of 0.671, which suggesting that the stock is 32.877% less volatile than S&P 500. In comparison Moderna has a beta of 2.231, suggesting its more volatile than the S&P 500 by 123.128%.

Walgreens Boots Alliance has a quarterly dividend of $0.25 per share corresponding to a yield of 8.96%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Walgreens Boots Alliance pays -14.59% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Walgreens Boots Alliance quarterly revenues are $39.5B, which are larger than Moderna quarterly revenues of $956M. Walgreens Boots Alliance's net income of -$265M is higher than Moderna's net income of -$1.1B. Notably, Walgreens Boots Alliance's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Walgreens Boots Alliance is 0.06x versus 3.29x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.